FORCE's eXamining the Relevance of Articles for You (XRAY) program looks behind the headlines of cancer news to help you understand what the research means for you.
XRAY is a reliable source of hereditary cancer research-related news and information.
Learn more about the XRAY program
All XRAYs
Relevance: High
Strength of Science: Medium-High
Research Timeline: Post Approval
Study : Genetic testing for inherited mutations may be helpful for all people with advanced or metastatic cancer
Relevance: High
Strength of Science: Medium-High
Research Timeline: Post Approval
Most relevant for: people with metastatic or recurrent cancer
In a study of nearly 12,000 cancer patients with a variety of cancers, eight percent of participants with metastatic cancer had an inherited mutation in a cancer gene that qualified them for a targeted treatment approved by the FDA or for participation in a clinical trial. The majority of people with metastatic cancer were unaware that they had an inherited mutation, and had not receive gene-directed treatment to which their tumor may have responded. The study authors suggest that genetic testing for inherited mutations may be warranted for all patients with advanced or metastatic cancer. (posted 9/30/21)
Este artículo está disponible en español.
Read More
Update : Blood tests called liquid biopsies for cancer screening, monitoring and treatment
Most relevant for: People considering a liquid biopsy to screen for cancer
Could a simple blood test change cancer detection, treatment and monitoring? Several companies are offering a type of blood test known as a liquid biopsy to detect multiple cancers at their earliest stages, monitor response to treatment and help choose the best treatment. Although progress has been made using liquid biopsies to treat cancer, these tests have not yet been shown to detect cancer early enough to save lives. (posted 9/29/21)
Este artículo está disponible en español.
Read More
Relevance: Medium
Strength of Science: Medium-High
Research Timeline: Post Approval
Study : Do sugared beverages increase the risk of early-onset colorectal cancer?
Relevance: Medium
Strength of Science: Medium-High
Research Timeline: Post Approval
Most relevant for: Healthy people with an average colorectal cancer risk
A study of female nurses in the U.S. suggests that a high intake of sugar-sweetened beverages may increase the risk of colorectal cancer before age 50. However, researchers saw few early-onset colorectal cancer cases which limited the findings. (posted 9/21/21)
Este artículo está disponible en español.
Read More
Article : Transgender peoples' perspectives of being diagnosed with gender-associated cancer
Most relevant for: transgender people
An ABC News article provides viewpoints and data that conveys the added stress experienced by transgender and gender-nonconforming people when they are diagnosed with gender-associated cancer (e.g., ovarian or prostate cancer) that does not match their gender identity. (posted 9/13/21)
Este artículo está disponible en español.
Read More
Relevance: Medium-High
Strength of Science: High
Research Timeline: Post Approval
Update : Pembrolizumab receives FDA approval for people with early-stage, triple-negative breast cancer
Relevance: Medium-High
Strength of Science: High
Research Timeline: Post Approval
Most relevant for: People with early-stage, triple-negative breast cancer who have a high risk for recurrence
The FDA approved the immunotherapy drug pembrolizumab (Keytruda) for the treatment of early-stage triple-negative breast cancer that has a high risk for recurrence. This marks the first approval for this type of drug, known as an immune checkpoint inhibitor, for the treatment of early-stage breast cancer. (posted 9/2/21)
Este artículo está disponible en español.
Read More
Relevance: High
Strength of Science: Medium-High
Research Timeline: Post Approval
Study : Drinking coffee or tea may improve survival after breast cancer
Relevance: High
Strength of Science: Medium-High
Research Timeline: Post Approval
Most relevant for: Women with breast cancer who drink coffee or tea.
In a study of 8,900 women with stage 1, 2 or 3 breast cancer, those who drank coffee survived longer after a breast cancer diagnosis than those who did not drink coffee. Both coffee and tea were linked to improved survival from any cause. Several factors were linked to greater coffee or tea consumption, so this finding must be taken with some caution. However, breast cancer survivors who are regular coffee or tea drinkers may find this research reassuring. (posted 8/31/21)
Este artículo está disponible en español.
Read More
Relevance: High
Strength of Science: High
Research Timeline: Post Approval
Study : Frequency of inherited mutations linked to breast cancer are similar in Black and white women
Relevance: High
Strength of Science: High
Research Timeline: Post Approval
Most relevant for: Non-Hispanic Black and white women with breast cancer
The CARRIERS study looked at the rate of inherited mutations in women with and without breast cancer. In an extension of the CARRIERS study, researchers found no difference in the frequency of inherited mutations in breast cancer genes among Black and white women with breast cancer. A few individual genes differed in frequency: BRCA2 and PALB2 mutations were seen more often in Black women, while CHEK2 mutations were seen less often. Researchers concluded that race should not be used to determine who is referred for genetic testing. (posted 8/13/21)
Este artículo está disponible en español.
Read More
Relevance: Medium-High
Strength of Science: High
Research Timeline: Post Approval
Guideline : ASCO guidelines recommend olaparib for people with early-stage, high-risk breast cancer and an inherited BRCA mutation
Relevance: Medium-High
Strength of Science: High
Research Timeline: Post Approval
Most relevant for: People with early-stage HER2-negative breast cancer and an inherited BRCA mutation
The American Society of Clinical Oncology (ASCO) has updated their breast cancer treatment guidelines to include treatment with the PARP inhibitor olaparib (Lynparza) for one year after completing chemotherapy, surgery and radiation (if used) to improve outcomes of people with an inherited mutation in BRCA1 or BRCA2 with early-stage, HER2-negative breast cancer who have a high risk for recurrence. (posted 8/6/21) Update: Based on results from the OlympiA Study, the FDA approved olaparib as adjuvant treatment for people with an inherited BRCA mutation who have been diagnosed with early-stage HER2-negative breast cancer and are at high risk for recurrence. (03/11/2022)
Este artículo está disponible en español.
Read More
Update : Breast cancer disparities in Black Americans
Most relevant for: Black women in the US
The American Association for Cancer Research (AACR) released a 2020 report about cancer disparities among racial and ethnic groups in the United States. In this review, we highlight findings on the burden of breast cancer in Black women. (posted 8/5/21)
Este artículo está disponible en español.
Read More
Article : Overview of pancreatic cancer treatment options
Most relevant for: People with pancreatic cancer
This review looks at current strategies for pancreatic cancer care and potential future therapies. (posted 7/28/21)
Este artículo está disponible en español.
Read More